Microcystins are cyclic heptapeptides implicated in the impairment of liver function in various animals. They have two variable amino acid residues; in the case of the cyanotoxin MC-LR the variable amino acids are Leucine (L) and Arginine (R). Microcystin-LR is the most commonly found cyanotoxin and inhibits protein phosphatase type 1 and type 2A (PP1 […]
| Inventor | Institute |
|---|---|
| Caroline Murphy ; Richard O'Kennedy | Dublin City University |
| Cat. #: | 158335 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Biochemistry |
| Application: | ELISA ; WB |
| Target: | Microcystin-LR |
| Host: | Mouse |
| Class: | Recombinant |
| Alternate name: | MC-LR, Anti-Microcystin-LR (R66S) scAb |
|---|---|
| Product description: | Microcystins are cyclic heptapeptides implicated in the impairment of liver function in various animals. They have two variable amino acid residues; in the case of the cyanotoxin MC-LR the variable amino acids are Leucine (L) and Arginine (R). Microcystin-LR is the most commonly found cyanotoxin and inhibits protein phosphatase type 1 and type 2A (PP1 and PP2A) activities in the cytoplasm of liver cells, leading to hepatocytic necrosis and haemorrhaging. Chronic exposure to microcystin is a worrying phenomenon as microcystin over an extended period of time can cause cancer through the inhibition of protein phosphatases PP1 and PP2A. |
| Conjugation: | Unconjugated |
| Immunogen: | Microcystin-LR |
| Immunogen Uniprot ID: | TBC |
| Target background: | Microcystins are cyclic heptapeptides implicated in the impairment of liver function in various animals. They have two variable amino acid residues; in the case of the cyanotoxin MC-LR the variable amino acids are Leucine (L) and Arginine (R). Microcystin-LR is the most commonly found cyanotoxin and inhibits protein phosphatase type 1 and type 2A (PP1 and PP2A) activities in the cytoplasm of liver cells, leading to hepatocytic necrosis and haemorrhaging. Chronic exposure to microcystin is a worrying phenomenon as microcystin over an extended period of time can cause cancer through the inhibition of protein phosphatases PP1 and PP2A. |
|---|
| Format: | Liquid |
|---|---|
| Storage conditions: | Store at -20° C frozen (best practice). Avoid repeated freeze/thaw cycles. Stable at room temperature in the presence of 20% (v/v) glycerol. |
| Shipping conditions: | Dry ice |
| References: |
Murphy et al. 2018. J Immunol Methods. 463:127-133. PMID: 30321550. |
|---|
Fig. 1. (A) The avian derived IgY molecule consists of four linked polypeptide chains; two heavy domains (containing one variable heavy region (VH); and four constant heavy regions (CH1; CH2; CH3 and CH4)) and two light domains (containing one variable light (VL) and one constant light (CL) region); linked by two disulphide bonds (shown in red) (Murphy et al.; 2016). The antigen-binding region is composed of a variable light (VL) and variable heavy (VH) domain. The antibody is segregated into a Fragment antigen binding (Fab) and Fragment crystallizable (Fc) region. (B) Single chain fragment variable (scFv) displays structurally important complementarity determining regions (CDR); and consists of VH and VL domains linked by a serine-glycine linker. (C) The single chain antibody (scAb) fragment is composed of a human kappa light chain constant domain (CL) connected to a scFv.

| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.